Canadian Treat and Extend Analysis Trial With Ranibizumab — CAN-TREAT  

wetAMD Clinical Trial

Official title: Canadian Treat and Extend Analysis Trial With Ranibizumab

Status Completed

Clinical Trial Summary

This is an observational study to will evaluate and compare two Ranibizumab treatment regimens (Standard of care) in patients with neovascular (wet) age-related macular degeneration (wAMD) aiming to achieve and to maintain a maximum visual function benefit. The results will be used to generate further recommendations on the timing of treatment administration for patients with neovascular (wet) age-related macular degeneration (wAMD). In this context, the study will use the anatomical imaging (for example, optical coherence tomography [OCT]) to evaluate wAMD disease activity impacted by the recurrence of disease instability and for decision making in the treatment decision algorithm.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• wetAMD

• NCT number: NCT02103738
• Study type: Observational
• Source: Novartis
• Status: Completed
• Start date: May 8, 2013
• Completion date: July 31, 2019